Short answer
AtriCure, Inc. (ATRC) filed its Q3 2025 10-Q quarterly report on Oct 30, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $134M (up 15.8% year over year) with net income of −$267,000.
Q3 2025 key financials · XBRL
- Revenue
- $134M
- +15.8% YoY · −1.4% QoQ
- Net income
- −$267,000
- +96.6% YoY · +95.7% QoQ
- Operating margin
- 0.2%
- Gross margin
- 75.5%
- EPS (diluted)
- −$0.01
- +94.1% YoY · +92.3% QoQ
Source: XBRL data from the AtriCure, Inc. (ATRC) Q3 2025 10-Q on SEC EDGAR. USD.
AtriCure, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- No newly added risk factors this quarter; no material changes since 2024 10-K annual report
- Most materially updated risk: None disclosed; risk factors unchanged from prior filings including Q1 2025 10-Q
- Regulatory risk: Compliance with Sarbanes-Oxley Act certifications for executive officers reaffirmed in exhibit filings
- Operational risk: No new references; ongoing risks remain as per 2024 10-K, no updates on competitive or market conditions
- Financial risk: No updates on liquidity, debt maturity, currency exposure, or concentration risks reported in this quarter
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other AtriCure, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.